Expertise in Preclinical Metabolic Disease Research

KCI Biotech is a leading metabolism-focused preclinical CRO providing comprehensive research solutions for metabolic disorders. We specialize in developing and validating animal models of metabolic diseases that accurately mimic human pathophysiology.

Our metabolic CRO services support pharmaceutical and biotechnology clients in drug discovery, mechanism exploration, and efficacy evaluation across a wide range of metabolic indications. Each study is conducted under GLP-compliant conditions, ensuring data quality, reproducibility, and scientific integrity throughout every project stage.

Why Use Animal Models in Metabolic Disease Research

Animal models play a vital role in understanding the pathogenesis and progression of metabolic diseases such as obesity, diabetes, and NASH. Since these disorders involve complex interactions among genetic, dietary, and environmental factors, in vivo metabolic disease models allow researchers to simulate human metabolic processes under controlled conditions. Working with a dedicated preclinical partner provides the controlled conditions and objective data required to translate preclinical discoveries into clinical applications.

Our Portfolio of Metabolic Disease Models

KCI Biotech has developed a validated suite of animal models for metabolic disease, supporting comprehensive preclinical evaluation of novel therapeutics. Built under GLP-compliant standards, these preclinical metabolic models simulate key pathological mechanisms such as insulin resistance, lipid accumulation, fibrosis, and inflammatory injury.

Our metabolic disease models encompass diet-induced, chemically induced, and genetic systems that cover major indications such as obesity, diabetes and its complications, hyperlipidemia, NASH, acute liver injury, and liver fibrosis. These models enable mechanism-driven exploration and efficacy validation in both in vivo metabolic disease CRO and translational research settings.

Through this integrated metabolic CRO service platform, KCI Biotech provides reliable and reproducible data to accelerate drug discovery and development in metabolic and endocrine disorders.

Obesity & Metabolism Models

We offer diverse obesity animal models to study weight regulation and lipid accumulation. As an advanced obesity and metabolism mouse models cro, our platform routinely utilizes the standard DIO mouse model, alongside genetic variants like the ob/ob mouse obesity model and high-fat diet-induced systems.

Diabetes & Complications Models

As an experienced diabetes CRO, we provide comprehensive models for both Type I and Type II diabetes. Available animal models for diabetes include STZ-induced Type I models and db/db Type II models. For researchers seeking a reliable animal model diabetes setup, our portfolio also covers complications like diabetic nephropathy, peripheral vasculopathy, and STZ-induced foot ulcers.

NASH & Acute liver injury

• Model of MCD feed-induced NASH
• Model of NASH induced by a high-fat, high-cholesterol, high-fructose feed
• Model of NASH induced by high-fat feed + streptozotocin (STZ)
• Acetaminophen (APAP)-induced acute liver injury model
• Carbon tetrachloride-induced acute liver injury model
• Cona-induced acute liver injury model

Obesity&Diabetes& Complications of diabetes

• Model of high-fat diet-induced obesity
• ob/ob mouse obesity model
• Type II diabetes model in db/db mice
• Streptozotocin (STZ)-induced type I diabetes mellitus model
• Model of type II diabetes induced by high-fat diet + streptozotocin (STZ)
• ZDF rat model of diabetes nephropathy

Comprehensive Metabolic CRO Solutions

KCI Biotech delivers integrated preclinical solutions for metabolic drug discovery. As your trusted obesity CRO and metabolic research partner, we ensure reliable execution and objective data interpretation:

Extensive Portfolio: The platform encompasses a variety of specific metabolic models within a broader catalog of over 500 validated disease models.

Species Capacity: Studies are conducted across mice, rats, hamsters, rabbits, dogs, and non-human primates within an 18,000 m² AAALAC-accredited environment.

Evaluation Platforms: The evaluation framework integrates in vivo metabolic monitoring, clinical pathology, tissue triglyceride assays, and bioanalytical research.

Proven Track Record: With over 200 IND filings (NMPA/FDA) supported and 500+ clients served, we guarantee high-quality translational data.

End-to-End Preclinical Services & Partnership

KCI Biotech’s workflow encompasses the entire preclinical research cycle—from study planning to final reporting:

Consultation & Design: Literature review and customized protocol development.

Execution & Quality: Model establishment, dosing, GLP documentation, and raw data verification.

Reporting & Archiving: Final report delivery and secure data storage.

With a multidisciplinary scientific team boasting decades of in vivo research experience, KCI Biotech strives to advance the understanding of metabolism-related diseases. Partner with us to transform discovery into therapeutic success. For more information, please contact us today.